News archive
Showing 742 results
May 2013
-
Media Release
Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
-- At six months, adjusted mean treatment satisfaction scores increased by a statistically significant 20.4 with Gilenya vs. 2.9 with injectable disease modifying therapies1-- In one of the largest… -
Media Release
Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
-
Media Release
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
- Latest Phase III research on Afinitor® in advanced HER2 positive breast cancer- Jakavi™ overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-… -
Media Release
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
April 2013
-
Media Release
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
- Discounts and rebates by pharmaceutical companies are a customary, appropriate and legal practice as recognized by the Government- Physician speaker programs are also an accepted practice designed… -
Media Release
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
March 2013
-
Media Release
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
- TOBI Podhaler is portable and requires no nebulizer, refrigeration or power source to deliver the medicine- TOBI Podhaler is indicated for certain cystic fibrosis (CF) patients with Pa and shortens… -
Media Release
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
-
Media Release
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1-- Gilenya is the first oral… -
Media Release
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies